Spero Therapeutics, Inc. Stock Issued During Period, Value, Conversion of Units
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for the quarter ending 2026-06-30 was $0.00.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for the quarter ending 2026-03-31 was $2.00K, a 100.00% increase year-over-year.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for the quarter ending 2025-09-30 was $0.00.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for fiscal 2025 was $1.00K, a 50.00% decline from fiscal 2024.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for fiscal 2024 was $2.00K, a 100.00% increase from fiscal 2023.
- Spero Therapeutics, Inc. stock issued during period, value, conversion of units for fiscal 2023 was $1.00K.
| Period end | Stock Issued During Period, Value, Conversion of Units 3 month | Stock Issued During Period, Value, Conversion of Units 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-13 | $2.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-13 | $2.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.00K 10-Q · filed 2025-05-13 | $1.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |